SIC
ACAD icon

SJS Investment Consulting’s Acadia Pharmaceuticals ACAD Stock Holding History

SJS Investment Consulting’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.93K Buy
195
+163
+509% +$3.59K ﹤0.01% 1390
2026
Q1 		$713 Sell
32
-9
-22% -$215 ﹤0.01% 1599
2025
Q4 		$1.1K Buy
41
+32
+356% +$765 ﹤0.01% 1270
2025
Q3 		$193 Hold
9
– – ﹤0.01% 1472
2025
Q2 		$195 Buy
+9
New +$167 ﹤0.01% 1374

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SJS Investment Consulting's ACAD Position: Q2 2026 in Review

SJS Investment Consulting increased its Acadia Pharmaceuticals (ACAD) stake by 509% in Q2 2026, buying an estimated $3.59K and bringing the position to 195 shares worth $4.93K. The position accounts for ﹤0.01% of the portfolio, ranked #1390.

SJS Investment Consulting first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • SJS Investment Consulting held 195 shares of Acadia Pharmaceuticals worth $4.93K as of Q2 2026.
  • SJS Investment Consulting bought 163 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.59K.
  • Acadia Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1390 holding.
  • SJS Investment Consulting first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.